Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The forefront of ovarian cancer therapy: update on PARP inhibitors
Mansoor Raza Mirza, Robert L. Coleman, Antonio González‐Martín, et al.
Annals of Oncology (2020) Vol. 31, Iss. 9, pp. 1148-1159
Open Access | Times Cited: 277

Showing 1-25 of 277 citing articles:

Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer
Kaiyang Zhang, Erdoğan Pekcan Erkan, Sanaz Jamalzadeh, et al.
Science Advances (2022) Vol. 8, Iss. 8
Open Access | Times Cited: 117
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Natalie Ngoi, David S.P. Tan
ESMO Open (2021) Vol. 6, Iss. 3, pp. 100144-100144
Open Access | Times Cited: 107
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
Valéria Tavares, Inês Soares Marques, Inês Guerra de Melo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1845-1845
Open Access | Times Cited: 34
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
Giorgio Bogani, Kathleen Moore, I. L. Ray-Coquard, et al.
Gynecologic Oncology (2025) Vol. 193, pp. 30-40
Closed Access | Times Cited: 7
DNA Damage Response and Immune Defense
Claudia Nastasi, Laura Mannarino, Maurizio D’Incalci
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 20, pp. 7504-7504
Open Access | Times Cited: 98
Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
Giorgio Valabrega, Giulia Scotto, Valentina Tuninetti, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4203-4203
Open Access | Times Cited: 77
BRAF Gene and Melanoma: Back to the Future
Margaret Ottaviano, Emilio Francesco Giunta, Marianna Tortora, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3474-3474
Open Access | Times Cited: 68
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
Shuangying Li, Liangliang Wang, Yuanyuan Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 63
Ferroptosis, necroptosis, and pyroptosis in the occurrence and development of ovarian cancer
Chunmei Zhang, Ning Liu
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 58
BRCA mutated pancreatic cancer: A change is coming
Michael N. Rosen, Rachel Goodwin, Michael M. Vickers
World Journal of Gastroenterology (2021) Vol. 27, Iss. 17, pp. 1943-1958
Open Access | Times Cited: 57
High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment
Veronica D. Gonzalez, Ying-Wen Huang, Antonio Delgado-González, et al.
Cell Reports (2021) Vol. 36, Iss. 9, pp. 109632-109632
Open Access | Times Cited: 56
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Ning Li, Youzhong Zhang, Jing Wang, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 22, pp. 2436-2446
Closed Access | Times Cited: 49
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
Stefanie Seitz, Tobias Dreyer, Christoph Stange, et al.
British Journal of Cancer (2022) Vol. 126, Iss. 10, pp. 1470-1480
Open Access | Times Cited: 42
Update on Emerging Therapies for Advanced Colorectal Cancer
Olatunji B. Alese, Christina Wu, William J. Chapin, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 27
cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer
Xiaomei Liang, Yulu Yang, Chuanqing Huang, et al.
Journal of Controlled Release (2023) Vol. 356, pp. 691-701
Closed Access | Times Cited: 24
PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials
István Baradács, Brigitta Teutsch, Alex Váradi, et al.
Journal of Ovarian Research (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 16
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
Susana Banerjee, Antonio González‐Martín, Philipp Harter, et al.
ESMO Open (2020) Vol. 5, Iss. 6, pp. e001110-e001110
Open Access | Times Cited: 65
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications
Roberto Moretto, Andrew Elliott, Jian Zhang, et al.
JNCI Journal of the National Cancer Institute (2021) Vol. 114, Iss. 2, pp. 271-279
Open Access | Times Cited: 52
Gut Microbiota and Gynecological Cancers: A Summary of Pathogenetic Mechanisms and Future Directions
Fulvio Borella, Andrea Roberto Carosso, Stefano Cosma, et al.
ACS Infectious Diseases (2021) Vol. 7, Iss. 5, pp. 987-1009
Closed Access | Times Cited: 51
Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing
Jianling Bi, A.M. Newtson, Yuping Zhang, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 2901-2901
Open Access | Times Cited: 47
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
Francesca Bizzaro, Ilaria Fuso Nerini, Molly A. Taylor, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 47
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
Jitka Fučíková, An Coosemans, Sandra Oršulić, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 10, pp. e002873-e002873
Open Access | Times Cited: 46
Overexpressed COL5A1 is correlated with tumor progression, paclitaxel resistance, and tumor‐infiltrating immune cells in ovarian cancer
Jinguo Zhang, Jihong Zhang, Fanchen Wang, et al.
Journal of Cellular Physiology (2021) Vol. 236, Iss. 10, pp. 6907-6919
Closed Access | Times Cited: 45
cAMP-Dependent Signaling and Ovarian Cancer
Agnieszka Kilanowska, Agnieszka Ziółkowska, Piotr Stasiak, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3835-3835
Open Access | Times Cited: 29
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Charles N. Landen, Luciana Molinero, Habib Hamidi, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 9, pp. 1698-1707
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top